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Summary
Background We aimed to accurately estimate the frequency of a hexanucleotide repeat expansion in C9orf72 that has been 
associated with a large proportion of cases of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Methods We screened 4448 patients diagnosed with ALS (El Escorial criteria) and 1425 patients with FTD (Lund-
Manchester criteria) from 17 regions worldwide for the GGGGCC hexanucleotide expansion using a repeat-primed 
PCR assay. We assessed familial disease status on the basis of self-reported family history of similar neurodegenerative 
diseases at the time of sample collection. We compared haplotype data for 262 patients carrying the expansion with 
the known Finnish founder risk haplotype across the chromosomal locus. We calculated age-related penetrance using 
the Kaplan-Meier method with data for 603 individuals with the expansion.
Findings In patients with sporadic ALS, we identiﬁ ed the repeat expansion in 236 (7·0%) of 3377 white individuals from 
the USA, Europe, and Australia, two (4·1%) of 49 black individuals from the USA, and six (8·3%) of 72 Hispanic individuals 
from the USA. The mutation was present in 217 (39·3%) of 552 white individuals with familial ALS from Europe and the 
USA. 59 (6·0%) of 981 white Europeans with sporadic FTD had the mutation, as did 99 (24·8%) of 400 white Europeans 
with familial FTD. Data for other ethnic groups were sparse, but we identiﬁ ed one Asian patient with familial ALS (from 
20 assessed) and two with familial FTD (from three assessed) who carried the mutation. The mutation was not carried by 
the three Native Americans or 360 patients from Asia or the Paciﬁ c Islands with sporadic ALS who were tested, or by 
41 Asian patients with sporadic FTD. All patients with the repeat expansion had (partly or fully) the founder haplotype, 
suggesting a one-oﬀ  expansion occurring about 1500 years ago. The pathogenic expansion was non-penetrant in individuals 
younger than 35 years, 50% penetrant by 58 years, and almost fully penetrant by 80 years.
Interpretation A common Mendelian genetic lesion in C9orf72 is implicated in many cases of sporadic and familial 
ALS and FTD. Testing for this pathogenic expansion should be considered in the management and genetic counselling 
of patients with these fatal neurodegenerative diseases.
Funding Full funding sources listed at end of paper (see Acknowledgments).
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neuro-
degenerative disease characterised by rapidly pro-
gressive paralysis and death from respiratory failure, 
typically within 3 years of symptom onset. The disease 
is inherited in about 5% of cases, following a clear 
Mendelian pattern, whereas most cases are classiﬁ ed as 
sporadic because they seem to arise at random.1 
Substantial progress has been made in understanding 
the genetic underpinnings of familial ALS.2 By contrast, 
the causes of sporadic or idiopathic ALS are far less 
well understood. Mutations in the known familial ALS 
genes—SOD1, FUS, and TDP-43—occur only rarely in 
sporadic cases (each accounting for less than 1·0% of 
cases);3–5 genome-wide association studies have 
identiﬁ ed few risk loci, and these have proved diﬃ  cult 
to replicate.6
Frontotemporal dementia (FTD) is a degenerative 
disorder of the frontal and anterior temporal lobes, and 
is a common form of dementia aﬀ ecting individuals 
younger than 65 years. The syndrome is characterised 
clinically by initial behavioural disturbances, followed 
by cognitive decline leading to dementia and death 
within a median of 7 years from symptom onset. Akin 
to ALS and other neurodegenerative diseases, a large 
proportion (~60·0%) of these cases are categorised as 
sporadic, and the causes of this idiopathic form of 
disease are largely unknown.7 A growing consensus 
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suggests that ALS and FTD form part of a continuum 
of neurological diseases that share a common 
pathological background, consisting of TAR DNA-
binding protein 43 (TDP-43)-positive inclusions within 
the CNS.8
We recently reported that a large hexanucleotide repeat 
expansion located within the non-coding portion of 
C9orf72 is the cause of chromosome 9-linked ALS 
and FTD.9,10 This genetic lesion accounted for a large 
proportion (~40·0%) of familial cases of ALS and FTD. 
The same mutation was present in nearly a quarter of 
apparently sporadic cases of ALS and FTD in the 
genetically homogeneous Finnish population, and in 
4·1% of sporadic cases of ALS and 3·0% cases of sporadic 
FTD from the USA. However, these estimates were based 
on relatively small cohorts drawn from a small number 
of institutions.
These ﬁ ndings prompted us to aim to estimate 
the frequency of this C9orf72 hexanucleotide repeat 
expansion more accurately, in a large cohort of European 
and US patients with sporadic ALS and sporadic FTD. 
We also examined the occurrence of this mutation in 
diverse non-white populations around the world.
Methods
Participants and study design
In this cross-sectional study, we screened 4448 patients 
diagnosed with ALS and 1425 patients diagnosed with 
FTD from 17 distinct regions worldwide. The appendix 
shows ethnic origin and clinical features of the patients. 
3860 patients had sporadic ALS, 1022 had sporadic FTD, 
588 had familial ALS, and 403 had familial FTD. Data for 
401 Finnish patients with ALS, 233 other Europeans with 
familial ALS, 75 Finnish patients with FTD, 340 Dutch 
patients with FTD, and 420 English patients with FTD 
have been published previously.10–12 All these cohorts were 
analysed to provide a comprehensive assessment of the 
global frequency of the expansion.
Patients with ALS were diagnosed according to the 
El Escorial criteria,13 and patients with FTD were 
diagnosed according to the Lund-Manchester criteria.14 
We classiﬁ ed patients’ disease as familial in nature on 
the basis of a diagnosis of ALS or FTD in any other 
family member (irrespective of relationship), as 
reported at the time of sample collection. We based 
ethnic and racial classiﬁ cation on self-reports from 
patients at the time of sample collection. Case numbers 
Sporadic ALS Sporadic FTD
n Carriers % (95% CI) n Carriers % (95% CI)
Europe*
Finnish 289 61 21·1% (16·5–26·3) 48 9 18·8% (8·9–32·6)
Swedish ·· ·· ·· 6 0 0% (0·0–45·9)
English 916 62 6·8% (5·2–8·6) 543 31 5·7% (3·9–8·0)
German 421 22 5·2% (3·3–7·8) ·· ·· ··
Dutch ·· ·· ·· 224 5 2·2% (0·7–5·1)
French ·· ·· ·· 150 14 9·3% (5·2–15·2)
Italian 465 19 4·1% (2·5–6·3) ·· ·· ··
Sardinian 129 10 7·8% (3·8–13·8) 10 0 0% (0·0–30·8)
Moldovan 3 0 0% (0·0–70·8) ·· ·· ··
Total (Europe) 2223 174 7·8% (6·7–9·0) 981 59 6·0% (4·6–7·7)
USA
White 890 48 5·4% (4·0–7·1) ·· ·· ··
Hispanic 72 6 8·3% (3·1–17·3) ·· ·· ··
Black 49 2 4·1% (0·5–14·0) ·· ·· ··
Native American 3 0 0% (0·0–70·8) ·· ·· ··
Total (USA) 1014 56 5·5% (4·2–7·1) ·· ·· ··
Rest of the world
Middle Eastern* 1 0 0% (0·0–97·5) ·· ·· ··
Indian 31 0 0% (0·0–11·2) 31 0 0% (0·0–11·2)
Asian 238 0 0% (0·0–1·5) 10 0 0% (0·0–30·8)
Paciﬁ c Islander/Guam 90 0 0% (0·0–4·0) ·· ·· ··
Australian* 263 14 5·3% (2·9–8·8) ·· ·· ··
Overall 3860 244 6·3% (5·6–7·1) 1022 59 5·8% (4·4–7·4)
Data for Finnish (289 with ALS and 48 with FTD), English (333 with FTD), and Dutch (224 with FTD) patients were previously published,10–12 but are included here to establish 
global frequencies. ALS=amyotrophic lateral sclerosis. FTD=frontotemporal dementia. *All self-reported as white.
Table 1: Frequency of the pathogenic GGGGCC hexanucleotide repeat expansion of C9orf72 in patients diagnosed with sporadic ALS or sporadic FTD 
classiﬁ ed by region
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listed for European countries and Australia and the 
Middle East refer to self-reported white individuals 
from that region. Italian data are from a population-
based cohort that had been collected through the 
Piemonte ALS Registry, an ongoing population-based 
epidemiological study of ALS based in northwestern 
Italy.15 The remaining cohorts were recruited through 
medical centres and from repositories in various 
countries.
We also screened 2585 neurologically healthy control 
individuals from Australia (213 patients), Finland (478), 
Germany (309), the Human Gene Diversity Panel (300), 
mainland Italy (354), Sardinia (87), and the USA (844) for 
presence of the pathogenic repeat expansion. 1167 of 
these individuals have been reported elsewhere.10 None 
of the control individuals had been diagnosed with ALS, 
FTD, dementia, or any other neurodegenerative disease. 
Ethics committees from the respective institutions 
approved the study, and written informed consent was 
obtained from all patients and control individuals.
Procedures
We used our previously described10 repeat-primed 
PCR assay to screen patients and control individuals 
for the presence of the chromosome 9p21 GGGGCC 
hexanucleotide repeat expansion (see appendix for 
technical details). The assay allows samples to be 
categorised into those that carry a pathogenic repeat 
expansion (>30 repeats) and those that carry only wild-
type alleles (<20 repeats).
For haplotype analysis, we analysed genome-wide 
single-nucleotide polymorphism (SNP) data from 
262 patients who carried the repeat expansion. We 
previously reported the identiﬁ cation in the Finnish 
population of a 42-SNP founder haplotype across the 
232 kb block of chromosome 9p21 where the pathogenic 
hexanucleotide expansion was ultimately established.16,17 
In this study, we used a custom perl software script 
to compare unphased sample genotype data with the 
42-SNP founder risk haplotype.16
We estimated mutation ages for all populations 
separately with the DMLE+ version 2.3 Bayesian linkage 
disequilibrium gene mapping package.18 Mutation ages 
were iterated for 10 000 burn-in iterations and a further 
10 000 iterations of the maximum-likelihood model. To 
obtain generalisable estimates of age of the repeat per 
population, we used median values of binned estimates 
passing the α threshold of 0·05 per iteration.
Statistical analysis
We calculated 95% CIs for proportions with the Clopper-
Pearson exact method. We estimated penetrance of the 
GGGGCC hexanucleotide repeat expansion in relation to 
the patients’ age on the basis of data available for 
603 mutant-gene carriers with the Kaplan-Meier method 
using the survival package within R statistical software 
(version 2.9.0), but substituting patient age at symptom 
onset for survival time.19 We assessed diﬀ erences between 
groups with the χ² test for discrete variables such as sex, 
family history, and site of onset. 
Familial ALS Familial FTD
n Carriers % (95% CI) n Carriers % (95% CI)
Europe*
Finnish 112 52 46·4% (37·0–56·1) 27 13 48·1% (28·7–68·0)
Swedish ·· ·· ·· 1 1 100·0% (2·5–100·0)
English 98 45 45·9% (35·8–56·3) 170 28 16·5% (11·2–22·9)
Irish 1 1 100·0% (2·5–100·0) ·· ··
German 69 15 21·7% (12·7–33·3) 29 4 13·8% (3·9–31·7)
Dutch ·· ·· ·· 116 30 25·9% (18·2–34·8)
French ·· ·· ·· 50 22 44·0% (30·0–58·7)
Italian 90 34 37·8% (27·8–48·6) ·· ·· ··
Sardinian 19 11 57·9% (33·5–79·7) 7 1 14·3% (0·4–57·9)
Total (Europe) 389 158 40·6% (35·7–45·7) 400 99 24·8% (20·6–29·3)
USA* 163 59 36·2% (28·8–44·1) ·· ·· ··
Rest of the world
Middle Eastern* 2 0 0% (0·0–84·2) ·· ·· ··
Israeli* 14 3 21·4% (4·7–50·8) ·· ·· ··
Asian 20 1 5·0% (0·1–24·9) 3 2 66·7% (9·4–99·2)
Overall 588 221 37·6% (33·7–41·6) 403 101 25·1% (20·9–29·6)
Data for Finnish (112 with ALS and 27 with FTD), English (87 with FTD), German (41 with ALS), Italian (29 with ALS), US (163 with ALS), and Dutch (116 with FTD) patients were 
previously published,10–12 but are included here to establish global frequencies. ALS=amyotrophic lateral sclerosis. FTD=frontotemporal dementia. *All self-reported as white.
Table 2: Frequency of the pathogenic GGGGCC hexanucleotide repeat expansion of C9orf72 in patients diagnosed with familial ALS and familial FTD 
classiﬁ ed by region
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Results
Table 1 and the appendix show the frequency of the 
C9orf72 hexanucleotide repeat expansion in patients 
diagnosed with sporadic ALS and sporadic FTD from 
diﬀ erent geographical regions. Data for 289 patients 
with sporadic ALS and 605 with sporadic FTD have been 
reported elsewhere.10–12 The pathogenic expansion was 
identiﬁ ed in 236 (7·0%) of 3377 white patients from the 
USA, Europe, the Middle East, and Australia, two (4·1%) 
of 49 black patients from the USA, and six (8·3%) of 
72 Hispanic patients from the USA who were diagnosed 
with sporadic ALS. The rate of the pathogenic expansion 
was lower in sporadic FTD: 59 (6·0%) of 981 white 
patients from Europe carried the mutation. By contrast, 
the GGGGCC repeat expansion was not present in 
patients of Native American, Asian, or Paciﬁ c Islander 
origin who had sporadic disease (table 1), although this 
might reﬂ ect the smaller size of the cohorts screened in 
these populations.
In addition to sporadic cases, we screened 588 familial 
cases of ALS and 403 familial cases of FTD for the 
presence of the C9orf72 repeat expansion (table 2, 
appendix). Of these, 345 patients with familial ALS and 
230 with familial FTD have been reported elsewhere.10–12 
Overall, 221 (37·6%) of 588 patients with familial ALS 
and 101 (25·1%) of 403 patients with familial FTD 
carried the genetic lesion, reinforcing our previous 
ﬁ ndings that this mutation was responsible for an 
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Figure 1: Finnish risk haplotypes across the chromosome 9p21 region in 262 patients with amyotrophic lateral sclerosis and the C9orf72 mutation
The previously identiﬁ ed Finnish risk haplotype is shown below the graph (27 357 278–27 589 746 bp; NCBI build 36; 42 single nucleotide polymorphisms [SNPs]).16 
Underneath the haplotype is a binary representation of the same data, with red circles at SNP positions where the haplotype has the less common allele at that site. In 
the graph, individual patients are shown as horizontal lines showing the extent to which they share the risk haplotype. The vertical black dashed line shows the 
location of the C9orf72 hexanucleotide repeat expansion. Recombination rates (centimorgans per megabase [cM/Mb]) from phase 2 Centre d’Etude du 
Polymorphisme Humain (CEPH) samples of HapMap are shown with a grey line.
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unparalleled proportion of cases of these diseases.10 We 
identiﬁ ed one Japanese individual diag nosed with 
familial ALS who carried the hexanucleotide repeat 
expansion. We also showed that one patient with 
familial FTD from Lund, Sweden, carried the expansion, 
suggesting that the chromosome 9p21 genetic lesion 
might be responsible for the geographical cluster of 
patients with FTD noted in that region.20
Of 2585 neurologically healthy control samples 
screened for the C9orf72 repeat expansion, ﬁ ve (0·2%) 
were carriers: two were previously reported elderly 
individuals from Finland,10 and the other three were 
individuals younger than 40 years from Germany and the 
USA (appendix).
Within Europe, the highest mutation frequency was 
noted in the Finnish population (21·1% of patients with 
sporadic ALS and 18·8% of patients with sporadic FTD).10 
About 6% of patients with sporadic ALS from Germany 
and England carried the expansion, whereas Italian 
patients with ALS had a lower rate (4·1%). 7·8% of 
patients with sporadic ALS from the genetically isolated 
island population of Sardinia had the mutation and the 
Dutch population had the lowest detected rate observed 
in European countries (2·2% of sporadic cases of FTD). 
White populations from Australia and the USA had an 
intermediate rate, with about 5·0% of patients with 
sporadic ALS carrying the pathogenic repeat expansion, 
perhaps because of the population and immigration 
histories of these countries.
Haplotype analysis suggested that every patient carrying 
the pathogenic GGGGCC repeat expansion also shared 
the Finnish founder risk haplotype, at least in part 
(ﬁ gure 1). Furthermore, patients with sporadic and 
familial disease carried the same founder risk haplotype. 
These ﬁ ndings suggest that the pathogenic hexanucleotide 
repeat expansion in C9orf72 might have occurred on one 
occasion in human history and sub sequently disseminated 
throughout these populations. Analysis of haplotype 
sharing between these cases estimated the age of C9orf72 
repeat expansion to be about 1500 years old (representing 
a median of 100·5 generations [IQR 57·6–127·6], 
assuming a generation is 15 years old).
In analysis of age-related penetrance (ﬁ gure 2), the 
pathogenic expansion was non-penetrant in carriers who 
were younger than 35 years of age, increasing to 50% 
penetrance by 58 years, and to almost full penetrance 
by 80 years. We noted no diﬀ erence between disease 
penetrance according to familial status, ALS or FTD 
diagnosis, sex, or age of symptom onset in patients with 
ALS or FTD (appendix).
Table 3 shows clinical details of patients carrying 
the hexanucleotide repeat expansion. Patients with ALS 
and the pathogenic repeat expansion were more likely 
to be female (p=0·0008), have a family history of disease 
(p<0·0001), and to have bulbar-onset disease (p=0·0011) 
than were patients who did not carry the expansion. 
Patients with FTD carrying the repeat expansion were 
also more likely to have a family history of disease 
(p<0·0001) and to present with behavioural variant FTD 
(p<0·0001).
Discussion
Our data show that the C9orf72 hexanucleotide repeat 
expansion is the most frequent cause of sporadic ALS 
and sporadic FTD identiﬁ ed thus far, accounting for 
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Figure 2: Age-related penetrance of the GGGGCC hexanucleotide repeat expansion in C9orf72
Kaplan-Meier analysis of 603 mutant-gene carriers (212 patients with familial amyotrophic lateral sclerosis, 
234 with sporadic amyotrophic lateral sclerosis, 99 with familial frontotemporal dementia, 53 with sporadic 
frontotemporal dementia, and ﬁ ve neurologically healthy controls). Age-related penetrance (ie, the proportion of 
mutant-gene carriers with manifestations of the disease by a given age) rose steadily, from 10% in patients 
younger than 45 years to almost 100% by the age of 80 years. The dotted lines shows the age at which 50% of the 
cohort developed symptoms. Vertical blue lines show censored events.
Amyotrophic lateral sclerosis Frontotemporal dementia
With expansion 
(n=465)*
Without expansion 
(n=3983)†
With expansion 
(n=160)‡
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(n=1265)§
Mean age at onset 
(range; SD)
56·8 (27·0–80·0; 
9·1)
58·7 (4·0–93·0; 
12·8)
57·5 (30·0–76·3; 
8·3)
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8·8)
Sex, male 232 (50·1%) 2251 (58·4%) 87 (54·4%) 683 (55·4%)
Positive family history 221 (47·5%) 367 (9·2%) 101 (63·1%) 302 (23·9%)
Presentation
Bulbar 139 (33·1%) 933 (26·0%) ·· ··
Limb 281 (66·9%) 2655 (74·0%) ·· ··
Behavioural variant ·· ·· 106 (85·5%) 685 (65·6%)
Progressive 
non-ﬂ uent aphasia
·· ·· 11 (8·9%) 165 (15·8%)
Semantic dementia ·· ·· 7 (5·6%) 195 (18·6%)
Data are mean (range; SD) or n (%). *Data not available for age at onset for 19 patients and site of onset for 
45 patients. †Data not available for age at onset for 305 patients, sex for 130 patients, and site of onset for 
395 patients. ‡Data not available for age at onset for eight patients and site of onset for 36 patients. §Data not 
available for age at onset for 71 patients, sex for32 patients, and site of onset for 220 patients.
Table 3: Demographic and clinical features of patients classiﬁ ed by diagnosis and by carrier status for the 
GGGGCC hexanucleotide repeat expansion in C9orf72
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about 5·0–7·0% of cases in white Europeans, Americans, 
and Australians in our large cohort. These frequency 
rates were slightly higher than were estimates from 
smaller cohorts obtained at one institution.9 Before 
identiﬁ cation of the genetic lesion underlying 
chromosome 9-linked ALS and FTD, mutations in the 
SOD1 gene were the most common known genetic 
cause of sporadic ALS (accounting for 0·7% of cases in 
a population-based cohort),3 whereas mutations in the 
PGRN gene were the most common known cause of 
sporadic FTD (3·0–4·0% in clinic referral series).21 The 
high frequency of the pathogenic expansion in our 
cohort is consistent with previous genome-wide 
association studies that identiﬁ ed the association signal 
on chromosome 9p21 as the only replicable locus in the 
sporadic form of ALS and FTD.16,22–24 Our ﬁ ndings 
conﬁ rm the importance of genetics in the pathogenesis 
of the idiopathic form of these neurodegenerative 
diseases.
Our haplotype data suggest that the pathogenic 
GGGGCC hexanucleotide repeat expansion in C9orf72 
arose from a one-oﬀ  mutation event16,17 that occurred 
about 1500 years ago. The geographical distribution of 
the mutation suggests that the mutation appeared in 
northern Europe and spread from there. Alternatively, 
the high frequencies in Finland and other isolated 
populations could be explained by the history of these 
communities. Finland and Sardinia are comparatively 
isolated regions, and have genetically homogeneous 
populations that originated from a small number of 
founders.25 Genetic drift has had a large inﬂ uence on 
allele frequencies in these populations and could explain 
the high occurrence of the mutation in these geographical 
isolates.
Recognition that all patients carrying the C9orf72 repeat 
expansion share a common ancestor has important 
implications for the interpretation of global frequency 
data for this mutation. Although the hexanucleotide repeat 
expansion is common in white Europeans, it is also 
present in black and Hispanic populations in the USA and 
individuals from Israel. This ﬁ nding probably reﬂ ects the 
scale and nature of past human migration and inter-
marriage between ethnic groups. Similarly, the relative 
absence of the pathogenic hexanucleotide repeat in India, 
Asia, and the Paciﬁ c Islands might be explained by the 
greater physical distances of these regions from Europe, 
and the consequent lack of admixture between populations. 
Notably, the one Japanese patient who we identiﬁ ed as a 
carrier of the C9orf72 expansion carried the Finnish risk 
haplotype, reinforcing the notion that the expansion 
occurred on one occasion in the past.
The sharing of a common risk haplotype in the 
C9orf72 region of chromosome 9p21 in patients with 
sporadic and familial ALS suggests that these apparently 
sporadic cases are actually cryptically related familial 
cases. This scenario might have occurred for several 
reasons, including unfamiliarity with the pedigree on 
the part of the patient or neurologist or because previous 
generations might have died at a young age before 
onset of neurological symptoms. The median age at 
onset in patients with the expansion was 57 years, and 
life expectancy in the USA began to exceed this point 
only in the early 1940s.26 Furthermore, the incomplete 
penetrance of the mutation, in which not all individuals 
carrying the expansion manifest a clinical phenotype, 
might be a contributing factor in apparently sporadic 
disease. In deed, we have reported symptom onset in 
the ninth decade of life in patients carrying the 
expansion and also encountered two elderly, 
neurologically healthy indi viduals with the expansion. 
Thus, the penetrance of this mutation seems to be 
complete only at a late stage of life, which is an 
observation of particular relevance for genetic 
counselling of healthy individuals carrying the 
expansion. The molecular biological substrate 
underlying this variability in age at onset is unclear: it 
might be driven by diﬀ erences in expansion lengths 
between patients, by age-related methylation across the 
locus, or by genetic factors elsewhere in the genome.
We compared our results with those of previous 
studies that reported the frequency of the C9orf72 
hexanucleotide repeat expansion in the pathogenesis of 
ALS and FTD (panel). Data were available from seven 
studies (appendix). Our study screened one of the 
largest cohorts of cases of ALS and FTD assessed to 
date, and also provides an initial report of the frequency 
of the pathogenic repeat expansion in non-white 
patients, a detailed examination of the haplotype across 
the locus, and an initial estimate of age-related disease 
Panel: Research in context
Systematic review
We searched Medline up to December, 2011, without language restrictions for relevant 
publications and selected studies that reported the GGGGCC hexanucleotide repeat 
expansion in C9orf72 in pathogenesis of amyotrophic lateral sclerosis (ALS) or 
frontotemporal dementia (FTD). On the basis of these criteria, seven studies were 
identiﬁ ed for further assessment (appendix). The number of patients screened for the 
pathogenic repeat expansion and the phenotype and ethnic origin reported by these 
studies are summarised in the appendix.
Interpretation
We report the frequency of the C9orf72 repeat expansion in a large cohort of patients 
with sporadic ALS and sporadic FTD. We also screened a large number of non-white 
patients for the expansion, and present frequency data for the mutation in these 
populations. We conﬁ rmed that the C9orf72 repeat expansion explains a substantial 
proportion of sporadic ALS (~7·0%) and sporadic FTD (~6·0%) cases in white populations. 
We also noted that patients with sporadic and familial disease carrying the expansion 
share a founder risk haplotype, suggesting that these patients have a common ancestor 
and that the original mutational event that led to the repeat expansion occurred only 
once in the past. We provide initial estimates of age-related penetrance, showing that 
50% of carriers manifest disease by 58 years of age, and that the mutation is fully 
penetrant by 80 years of age.
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penetrance in a large group of individuals carrying the 
expansion.
Our data have implications for the clinical care of 
patients diagnosed with ALS and FTD. The clinical 
standard of care is to oﬀ er genetic testing to patients 
reporting a family history of ALS or FTD,27 and to reassure 
patients classiﬁ ed as having sporadic disease that their 
relatives are not at increased risk of neuro degeneration. 
On the basis of an analysis of 191 Irish patients with ALS, 
Byrne and colleagues28 suggested that genetic testing for 
the C9orf72 repeat expansion is unnecessary in aﬀ ected 
individuals without a family history of disease or 
substantial cognitive impairment. By contrast, we believe 
that genetic testing is a valuable technique for accurate 
diagnosis of the two disorders and in the decision-making 
process for patients and their families. The discrepancy 
between these two views might stem from diﬀ erences in 
how sporadic and familial disease were deﬁ ned in the 
two studies. Accumulation of suﬃ  cient data is an 
important step towards answering this key question for 
management of patients. In view of the large number of 
patients who carry the repeat expansion, investigators 
and clinicians should at least consider a focused debate 
on this issue.
Our paper has some limitations. First, the number 
of patients from some geographical regions was small 
and the mutational frequencies might change for those 
ethnic groups as additional patients are screened. 
Never theless, our data for more than 5000 patients with 
ALS or FTD provide a reasonable estimation of C9orf72 
global frequency. Second, although we have examined 
the chromosome 9p21 haplotype in a large and diverse 
cohort of individuals carrying the pathogenic expansion, 
additional testing of carriers might reveal other 
haplotypes, thereby indicating that the expansion arose 
on more than one occasion. Nevertheless, our data 
suggest that most expansion carriers share a common 
ancestor.16,17 Third, we generated age-related penetrance 
estimates on the basis of data from retrospective 
cohorts, which potentially leads to overestimation of 
penetrance. Additional prospective studies examining 
family kindreds are necessary to conﬁ rm these 
estimates. Finally, case classiﬁ cation as familial or 
sporadic was done on the basis of clinical questioning 
at sample collection. The level of scrutiny might have 
varied between centres and countries, but re-collection 
of this information for existing cohorts was not 
feasible.
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